All > Fatty Liver

No Hepatic Impairment for Non-alcoholic Fatty Liver Disease (NAFLD)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Non-alcoholic Fatty Liver Disease (NAFLD)Miricorilant - Drug
Eligibility
18 - 75
All Sexes
What conditions do you have?
Select

Study Summary

This trial will compare how well miricorilant works in people with different degrees of liver impairment.

Eligible Conditions
  • Non-alcoholic Fatty Liver Disease (NAFLD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
MAD Cohorts 1 to 4: Participants receiving ECC4703
1
Miricorilant Dose Escalation
1
Molnupiravir

Study Objectives

3 Primary · 5 Secondary · Reporting Duration: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 144 hours post-dose

Day 7
Number of Participants with Clinically-Significant Laboratory Test Abnormality
Hour 24
Number of Participants with Clinically-Significant Vital Sign Abnormality
Day 7
Electrocardiogram
Hour 144
AUC from Time Zero to Infinity (AUC0-∞)
Area under the Concentration-Time Curve (AUC) from Time Zero to the Last Non-Zero Concentration (AUC 0-t)
Maximum Observed Plasma Concentration (Cmax)
Day 30
Number of Participants with One or More Serious Adverse Events (SAEs)
Up to Day 7
Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
MAD Cohorts 1 to 4: Participants receiving ECC4703
1
Miricorilant Dose Escalation
1
Molnupiravir

Trial Design

3 Treatment Groups

No Hepatic Impairment
1 of 3
Moderate Hepatic Impairment
1 of 3
Mild Hepatic Impairment
1 of 3

Experimental Treatment

36 Total Participants · 3 Treatment Groups

Primary Treatment: No Hepatic Impairment · No Placebo Group · Phase 1

No Hepatic Impairment
Drug
Experimental Group · 1 Intervention: Miricorilant · Intervention Types: Drug
Moderate Hepatic Impairment
Drug
Experimental Group · 1 Intervention: Miricorilant · Intervention Types: Drug
Mild Hepatic Impairment
Drug
Experimental Group · 1 Intervention: Miricorilant · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 144 hours post-dose

Who is running the clinical trial?

Corcept TherapeuticsLead Sponsor
60 Previous Clinical Trials
4,848 Total Patients Enrolled
Joseph Custodio, PhDStudy DirectorCorcept Therapeutics
3 Previous Clinical Trials
118 Total Patients Enrolled

Eligibility Criteria

Age 18 - 75 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are female and non-childbearing or willing to use an acceptable intrauterine contraceptive device 4 weeks prior and throughout the study and for 90 days after study drug administration.
You are not currently engaging in heterosexual intercourse.
You have stable hepatic impairment (Child-Pugh [CP] class A or B according to group).
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top